BLC
JAZZ icon

Brown, Lisle/Cummings’s Jazz Pharmaceuticals JAZZ Stock Holding History

Brown, Lisle/Cummings’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17K Sell
9
-1
-10% -$219 ﹤0.01% 837
2026
Q1 		$1.89K Buy
+10
New +$1.75K ﹤0.01% 835

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Brown, Lisle/Cummings's JAZZ Position: Q2 2026 in Review

Brown, Lisle/Cummings reduced its Jazz Pharmaceuticals (JAZZ) stake by 10% in Q2 2026, selling an estimated $219 and leaving 9 shares worth $2.17K. The position accounts for ﹤0.01% of the portfolio, ranked #837.

Brown, Lisle/Cummings first reported a position in JAZZ in Q1 2026 and has held it in 2 quarters since. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Brown, Lisle/Cummings held 9 shares of Jazz Pharmaceuticals worth $2.17K as of Q2 2026.
  • Brown, Lisle/Cummings sold 1 Jazz Pharmaceuticals share in Q2 2026, an estimated $219.
  • Jazz Pharmaceuticals made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #837 holding.
  • Brown, Lisle/Cummings first reported a position in Jazz Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.